This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
In 2024, Israel also placed sanctions on the Houthis. In September 2026, the G7 foreign ministers issued a joint statement condemning Houthi attacks on Saudi Arabia and calling on Iran to end its support for the Houthis.
In April 2021 Noakes pleaded guilty in France to manufacturing and selling fake medicinal products and cosmetics by Internet and sentenced to 4 years of jail. A 2019 Business Insider report detailed the activities of Amanda Mary Jewell, who sold GcMAF for years as an unlicensed cure for several medical conditions, including cancer and autism. Jewell is not a medical doctor.
His researches made from 1899 to 1906 were published in 1907 with the title Untersuchungen über Aminosauren, Polypeptides und Proteine. Three years later the total number of peptides exceeded 100, with the longest being an 18 amino acid peptide containing 15 glycine and three leucine units. The 18 amino acid peptide gave the standard responses to tests for proteins used by physiological chemists - a positive Biuret test, precipitation by inorganic salts and cleavage by proteolytic enzymes
Limited/selective fasciectomy removes the pathological tissue, and is a common approach. A 2015 Cochrane review reported that low-quality evidence suggested that fasciectomy may be more effective for people with advanced Dupuytren's contractures. During the procedure, the person is under regional or general anesthesia. A surgical tourniquet prevents blood flow to the limb. The skin is often opened with a zig-zag incision but straight incisions with or without Z-plasty are also described and may reduce damage to neurovascular bundles. All diseased cords and fascia are excised. The excision has to be very precise to spare the neurovascular bundles. Because not all the diseased tissue is visible macroscopically, complete excision is uncertain. A 20-year review of surgical complications associated with fasciectomy showed that major complications occurred in 15.7% of cases, including digital nerve injury (3.4%), digital artery injury (2%), infection (2.4%), hematoma (2.1%), and complex regional pain syndrome (5.5%), in addition to minor complications including painful flare reactions in 9.9% of cases and wound healing complications in 22.9% of cases. After the tissue is removed the incision is closed. In the case of a shortage of skin, the transverse part of the zig-zag incision is left open. Stitches are removed 10 days after surgery. After surgery, the hand is wrapped in a light compressive bandage for one week. Flexion and extension of the fingers can start as soon as the anaesthesia has resolved. It is common to experience tingling within the first week after surgery.
Sources: en.wikipedia.org
The ineffectual response was caused by feuding officials who refused to co-operate with each other contributed to the death toll. It took weeks for aid to reach some villages, causing much resentment in Calabria. To offset widespread criticism that the government in Rome did not care about Calabria, King Victor Emmanuel III personally took over the relief operation and toured the destroyed villages of Calabria, which won the government a measure of popularity. Notably, after the king took charge, the feuding ceased and aid started to flow.
== Clinical governance == In January 2024, Eucalyptus appointed former Australian deputy chief medical officer Nick Coatsworth as a clinical governance adviser following scrutiny over the prescribing of compounded semaglutide.
Pd complexes of XPhos catalyze the amination and amidation of arylsulfonates and aryl halides. XPhos has also been used in the Pd-catalyzed borylation of aryl and heteroaryl chlorides Modified versions of XPhos, he more hindered t-BuXPhos and Me4tButylXPhos, have been employed in the formation of diaryl ethers. Incorporation of a sulfonate group at the 4-position allows this ligand to be used for Sonogashira couplings in aqueous biphasic solvents.
Sources: en.wikipedia.org
== History == In 1987, Dynacare Health Group acquired its first diagnostic laboratory—Quality Medical Laboratories and established Dynacare Laboratories. By 2015, Dynacare was part of the Central Medical Laboratories (CML), established in 1959 in Winnipeg, Manitoba. Dynacare was formed with the formation of an "operational partnership" in 1997 between Ontario's Bio-Science Laboratory and Gamma North Peel Partnership Inc. In 2002, Laboratory Corporation of America (LabCorp) acquired Dynacare Laboratories—one of the Dynacare partners—for US$480-million, while also assuming Dynacare debt worth $205-million. By 2002, Dynacare, just before LabCorp's takeover, had become the largest central clinical laboratory in western Canada, with a revenue in 2001 of $402.4-million and a profit of $11.7-million. By June 2020, DynaLIFE was operating 36 private laboratories in the Edmonton area and northern Alberta and had a contract with the Alberta government that is set to expire in 2022. In June 2020, Alberta Health Services, announced plans to outsource public community laboratory services to private companies. Gamma-Dynacare acquired LifeLabs Quebec. In 2013, DynaLIFE Medical Labs partnered with Dynacare, which operates laboratories in Alberta and across Canada. In 2015, Gamma-Dynacare Medical Laboratories rebranded itself back to Dynacare.
In Berezovka, a memorial steel was erected in 1972. In Bychivka Station: A memorial plaque was dedicated in 1965. In Dubrova: a Monument was erected in 1979 commemorating the 1943 raid on the local German Garrison.
=== Australia === From 1 July 2012 Chinese medicine practitioners must be registered under the national registration and accreditation scheme with the Chinese Medicine Board of Australia and meet the Board's Registration Standards, to practice in Australia.
However, Waley also testified that majority rule was not desirable immediately. Talks aimed at easing the differences between Rhodesia and the United Kingdom were carried out aboard Royal Navy vessels once in December 1966 and again in October 1968. Both efforts failed to achieve agreement, although Harold Wilson added a sixth principle to the five he had previously enunciated: "it would be necessary to ensure that, regardless of race, there was no oppression of the majority by the minority or of [any] minority by the majority." Rhodesian resolve stiffened following a failure to reach a new settlement, with more radical elements of the Rhodesian Front calling for a republican constitution. During a two-proposition referendum held in 1969, the proposal for severing all remaining ties to the British Crown passed by a majority of 61,130 votes to 14,327. Rhodesia declared itself a republic on 2 March 1970. Under the new constitution, a president served as ceremonial head of state, with the prime minister nominally reporting to him. Some in the Rhodesian government had hoped in vain that the declaration of a republic would finally prompt other nations to grant recognition.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.